• Licensing agree­ment in­cludes equity investment and poten­tial devel­op­ment, clin­i­cal, regu­la­tory and commercial mile­stones and tiered royalties
• Ayala retains world­wide rights to all other indi­ca­tions for AL102

Rehovot, Israel, and Wilmington, DE (Press Release) – Ayala Pharma­ceu­ticals, Inc., a clin­i­cal-stage com­pany devel­op­ing medicines for cancers that are genetically identified, announced today that it entered into an option to license agree­ment with Novartis for its inves­ti­ga­tional agent AL102 in multiple myeloma. Under the terms of the deal, Ayala will receive a $10 million equity investment from Novartis …